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Abstract
Hereditary hyperekplexia, or startle disease, is a neuromotor disorder caused mainly by mutations that either prevent the
surface expression of, or modify the function of, the human heteromeric a1 b glycine receptor (GlyR) chloride channel. There
is as yet no explanation as to why hyperekplexia mutations that modify channel function are almost exclusively located in
the a1 to the exclusion of b subunit. The majority of these mutations are identified in the M2–M3 loop of the a1 subunit.
Here we demonstrate that a1 b GlyR channel function is less sensitive to hyperekplexia-mimicking mutations introduced
into the M2–M3 loop of the b than into the a1 subunit. This suggests that the M2–M3 loop of the a subunit dominates the b
subunit in gating the a1 b GlyR channel. A further attempt to determine the possible mechanism underlying this
phenomenon by using the voltage-clamp fluorometry technique revealed that agonist-induced conformational changes in
the b subunit M2–M3 loop were uncoupled from a1 b GlyR channel gating. This is in contrast to the a subunit, where the
M2–M3 loop conformational changes were shown to be directly coupled to a1 b GlyR channel gating. Finally, based on
analysis of a1 b chimeric receptors, we demonstrate that the structural components responsible for this are distributed
throughout the b subunit, implying that the b subunit has evolved without the functional constraint of a normal gating
pathway within it. Our study provides a possible explanation of why hereditary hyperekplexia-causing mutations that
modify a1 b GlyR channel function are almost exclusively located in the a1 to the exclusion of the b subunit.
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Introduction
Imbalance between the excitatory and inhibitory neurotrans-
mission systems is the cause of many neurological disorders.
Human hereditary hyperekplexia (startle disease), which is
characterized by exaggerated startle reflexes and hypertonia in
response to sudden, unexpected auditory or tactile stimuli, is a
neuromotor disorder caused by dysfunction of inhibitory glyci-
nergic neurotransmission in the spinal cord [1]. The majority of
genetic mutations identified so far for this disorder have been
mapped onto the postsynaptic neurotransmitter receptor, the
glycine receptor (GlyR) chloride channel. The synaptic GlyR exists
predominantly as the heteromeric a1 b form [2]. However the
hereditary hyperekplexia-causing mutations of the GlyR are
almost exclusively located in the a1 to the exclusion of b subunit,
a fact which has puzzled the field for many years [1,3,4].
The GlyR, together with several other postsynaptic neurotrans-
mitter receptors including the nicotinic acetylcholine receptor
(nAChR), the type 3 5-hydroxytryptamine receptor (5HT3R), and
the type A c-aminobutyric acid receptor (GABAAR), belong to the
Cys-loop receptor ligand-gated ion channel superfamily, because
they share common structural and functional characteristics
[4,5,6]. The members of this superfamily exist as pentamers.
Each subunit is composed of an N-terminal extracellular domain
(ECD) and a transmembrane domain (TMD). The TMD is
comprised of four a-helical transmembrane segments (M1–M4)
and a large intracellular domain between M3 and M4. Agonists
bind to the receptor in a pocket that is formed by the principle (+)
and complementary (-) sides of adjacent ECDs. Agonist binding,
through a gating pathway, ultimately leads to the opening of a gate
in the channel pore, which is formed by the M2 TMDs
[7,8,9,10,11,12,13,14,15,16].
The putative stoichiometry of the a1 b GlyR is 2a1:3b [17],
although other stoichiometries may also be possible. The a1 b
GlyR has been shown to bind the agonist glycine at both the a+/
b2 and b+/a2 subunit interfaces, and agonist binding at either
interface is sufficient to activate the channel [17]. Therefore, it
seems that the a1 and b subunits play equivalent roles at the
agonist-binding level. However, how the a1 and b subunits
contribute to the downstream channel gating pathway is barely
known. Hyperekplexia-causing GlyR a1 mutations can be
classified into two groups: those that disrupt channel function
and those that reduce surface expression. Interestingly, most
mutations that disrupt GlyR channel function are concentrated
within the a1 subunit gating pathway [1,3] (Fig. 1). Therefore,
addressing the question of how the a1 and b subunits contribute to
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e28105the channel gating pathway is key to solving the puzzle of the
predominance of the GlyR a1 mutations in hereditary hyper-
ekplexia.
To address this question, we concentrated on one of the
essential structural components of the channel gating pathway, the
M2–M3 loop (Fig. 2A). Mutations in this region have been shown
to cause drastic effects on channel function in many members of
the Cys-loop receptor superfamily [18,19,20,21]. More impor-
tantly, this region of the GlyR a1 subunit hosts mutations
responsible for most cases of hereditary hyperekplexia, such as
R271(199)Q/L, K276(249)E, and Y279(279)C [1,4,20]. In addi-
tion, a systematic alanine-scanning of this region in the homomeric
a1 GlyR further reveals that mutations of a few other residues,
notably V277(259)A, also mimic the phenotype of hereditary
hyperekplexia-causing mutations [20]. The primed numbers in
brackets after the names of residues refer to the standard M2
domain numbering system that assigns 19 to the innermost M2
residue. This numbering system will be used henceforth as it
enables residues from different subunits to be compared.
In this study, we compared effects of hyperekplexia-mimicking
mutations in the M2–M3 loops of a1 and b subunits. We found
that a1 b GlyR channel function is less sensitive to mutations
introduced into the b than into the a1 subunit. We conclude that
the b subunit M2–M3 loop plays a minor role in a1 b GlyR
channel gating. A further attempt to identify the possible
mechanism underlying this phenomenon indicates that the
agonist-induced conformational changes in the b subunit M2–
M3 loop are uncoupled from a1 b GlyR channel gating. In
addition, we also discovered that the structural components
responsible for this are distributed throughout the b subunit,
implying that the b subunit has evolved without the functional
constraint of a normal gating pathway within it. Our study
provides a possible explanation of why hereditary hyperekplexia-
causing mutations that modify a1 b GlyR channel function are
almost exclusively located in the a1 to the exclusion of the b
subunit.
Results
a1 b GlyR channel function is less sensitive to
hyperekplexia-mimicking mutations introduced into the
M2–M3 loop of the b than into the a1 subunit
Previously we reported that a1 b GlyR channel function was
not sensitive to cysteine mutations introduced into the M2–M3
loop of the b subunit. We also showed that the channel function of
these cysteine-substituted a1 b GlyRs did not change in response
to treatment with a cysteine-reactive compound, 2-trimethylam-
moniumethylmethane thiosulfonate (MTSET) [22]. However,
there is a possibility that the cysteine mutations might cause
gain-of-function: for example, a disulfide bond could form
between the M2–M3 loops of adjacent subunits [23]. In addition,
the lack of response to MTSET treatment might be due to the
residue not being labeled by MTSET rather than not being
sensitive to MTSET modification. We therefore introduced the
functionally-inert Ala mutation to verify the results obtained from
these experiments.
The following hyperekplexia-mimicking mutations in the M2–
M3 loop were introduced, one at a time, to disrupt the channel
function: K249A, V259A, and Y279A (Fig. 2A). These mutations,
when introduced into the a1 subunit, each cause a dramatic
increase in glycine EC50 of the homomeric a1 GlyR [20], which in
principle could be due to compromised agonist binding, disrupted
channel gating, or a mixture of both [24]. As the M2–M3 loop is
spatially distant from the agonist binding site based on various
structures of Cys-loop receptor members [10,12,13,16] and is
temporally downstream from the agonist binding site in the channel
gating pathway based on single-channel kinetic analysis [9], the
increase in agonist EC50 values caused by the K249A, V259A, and
Y279A mutations can be attributed predominantly to a disrupted
channel gating efficacy. This hypothesis is supported by the results
of single-channel kinetic analyses on the M2–M3 loop mutants of
both the GlyR and nAChR [25,26]. Here we use the agonist EC50
asanindex ofchannelgatingefficacy changesto compare theeffects
of K249A, V259A, and Y279A mutations, when introduced into the
a1 versus b subunits, on channel gating. Similar strategies (using
either agonist EC50 values or voltages of half activation) have been
successfully employed to probe the gating mechanisms of both
ligand- and voltage-gated channels [27,28].
Fig. 2B shows sample currents recorded in response to glycine of
increasing concentrations in HEK293 cells expressing a1WT
bWT, a1K249A bWT and a1WT bK249A GlyRs. The glycine
concentration-response curve of the a1K249A bWT GlyR was
dramatically right-shifted relative to that of the a1WT bWT GlyR
(Fig. 2C). The a1K249A bWT GlyR exhibited an EC50 of
500680 mM, which was much higher than the corresponding
value, 1162 mM, recorded in the a1WT bWT GlyR (p,0.01,
Table 1). In contrast, the same mutation introduced into the b
subunit had no effect on the glycine EC50. The concentration-
response curve of the a1WT bK249A GlyR almost overlapped
that of the a1WT bWT GlyR (Fig. 2B and C), and the EC50 of the
a1WT bK249A GlyR was not significantly different from that of
the a1WT bWT GlyR (1361 mM versus 1162 mM, p.0.05,
Table 1).
As noted above, the degree to which channel gating is disrupted
is reflected by the increase in agonist EC50. Thus, the ratio of
mutant to WT glycine EC50 (RM/W) provides an index of the
Figure 1. Distribution of hereditary hyperekplexia-causing
mutations in the GlyR a1a n db subunits. The hereditary
hyperekplexia-causing mutations that disrupt the GlyR channel function
rather than block surface expression, are mapped onto the structure
models [3] of GlyR a1 (A52S, E103K, R218Q, S231N, I244N, P250T,
V260M, T265I, Q266H, S267N, R271L/Q, K276E and Y279C) and b
(G229D) subunits.
doi:10.1371/journal.pone.0028105.g001
b Subunit in a1 b Glycine Receptor Channel Gating
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RM/W in the following text to compare the degrees to which the
respective subunits contribute to channel gating. K249A when
introduced into the a1 subunit disrupted the a1 b GlyR channel
gating by a factor 45612, which is the EC50 of the a1K249A bWT
GlyR divided by the EC50 of the a1WT bWT GlyR (Table 1). On
the other hand, K249A when introduced into the b subunit
disrupted the a1 b GlyR channel gating by a factor 1.260.3,
which is the EC50 of the a1WT bK249A GlyR divided by the
EC50 of the a1WT bWT GlyR (Table 1).
As summarized in Fig. 2D and Table 1, virtually identical
results were obtained for V259A and Y279A. We thus conclude
that the a1 b GlyR gating efficacy is more affected when the
disruption of the gating pathway occurs in the a1 than in the b
subunit.
One potential problem in drawing such a conclusion is that
there is a possibility that the b subunit was not expressed and that
the recorded currents may have arisen from homomeric a1 GlyRs.
In such a case, no matter how the a1 and b subunits contribute to
the a1 b GlyR channel gating, mutations introduced into the M2–
Figure 2. Effects of M2–M3 loop mutations on a1 b GlyR channel function. (A) The positions where mutations were introduced, K249, V259
and Y279, are shown in red in a structure model of the GlyR a1 subunit (left panel). Their positions are also indicated in the amino acid sequences of
the M2–M3 loops of the a1 and b subunits (right panel). (B) Example traces of currents induced by increasing glycine concentrations in the indicated
receptors. (C) Averaged normalized glycine concentration–response curves for the a1WT bWT GlyR (N),a1WT bK249A GlyR (#) and the a1K249A bWT
GlyR (.). (D) The RM/Ws (the EC50 of the mutant a1 b GlyR divided by the EC50 of the WT a1 b GlyR) resulting from introducing the K249A, V259Ao r
Y279A mutation into the a1(N) and b (#) subunits are shown. (** p,0.01 using the Student’s t-test).
doi:10.1371/journal.pone.0028105.g002
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previously [20], and mutations introduced into the b subunit
would not affect channel function at all, and give results similar to
those we obtained. To eliminate this possibility and to maximize
the expression of heteromeric a1 b versus homomeric a1 GlyRs,
we transfected cells with a1 and b cDNAs in a ratio of 1:10.
Moreover, we tested the sensitivity of the glycine-induced current
to picrotoxin wherever there was a possibility that the recorded
current may have arisen from homomeric a1 GlyRs. The
heteromeric a1 b GlyR has been shown to be resistant to
picrotoxin blockade compared to the homomeric a1 GlyR
[29,30]. The magnitude of picrotoxin blockade can therefore
reflect the degree to which the heteromeric a1 b GlyR versus the
homomeric a1 GlyR has been expressed. In our experiments, only
those cells showing significant picrotoxin resistance (Table 1) were
used for further glycine concentration-response investigation.
The picrotoxin sensitivity testing was applied only to receptors
incorporating a1WT, a1K249A, and a1V259A subunits, as no
glycine-induced current was detected for the homomeric a1Y279A
GlyR (Table 1).
b subunit M2–M3 loop conformational changes are
uncoupled from a1 b GlyR channel gating
We next sought to determine the mechanism underlying the
asymmetrical contributions of the a1 and b subunits to channel
gating, i.e. how differently the M2–M3 loops of the a1 and b
subunits responded during a1 b GlyR channel gating. To achieve
Table 1. Properties of glycine induced currents of GlyRs recorded in the HEK293 cells.
Constructs
10uM PTX
inhibition (%)
100uM PTX
inhibition (%)
Glycine EC50
(mM) RM/W nH Imax (nA) n
WT
aWT bWT 8.561.8 33691 1 622 . 0 60.4 4.361.2 4
aWT a-bWT 3.862.2 25621 9 641 . 3 60.3 4.360.7 4
aWT b-aWT 8.561.9 26623 3 682 . 4 60.4 8.062.3 4
aWT aB-bWT 4.860.9 33641 6 631 . 8 60.4 8.661.6 5
aWT aT-bWT 3.260.6 25661 4 612 . 0 60.1 12.061.6 4
199
aR199A bWT 2.862.1 20695 9 0 670 54 611 2.560.3 3.961.3 4
aR199A bA199R4 . 2 61.7 22685 3 0 6120 48 614 2.160.2 5.560.9 5
249
aWT bK249A6 . 0 61.2 35631 3 611 . 2 60.3 1.560.3 5.461.0 3
aK249A bWT 2.261.1 20655 0 0 680 45612 1.860.2 6.361.1 4
aWT a-bK249A5 . 6 61.0 35642 5 641 . 3 60.3 1.560.2 8.061.8 4
aK249A a-bWT 4.860.7 26658 3 619 4.361.3 1.060.1 7.260.9 4
aWT b-aK249A 12.063.0 31633 6 610 1.160.4 1.560.3 5.961.7 4
aK249A b-aWT 10.062.2 23646 8 4 6157 21672 . 0 60.3 8.961.9 4
259
aWT bV259A5 . 7 62.2 36671 1 611 . 0 60.2 2.060.6 7.760.8 3
aV259A bWT 4.760.7 38637 7 8 6144 71620 1.460.2 7.462.8 3
aWT a-bV259A3 . 0 61.3 34641 5 64 0.7960.26 1.360.1 7.661.7 4
aV259A a-bWT 2.960.8 21659 7 627 5.161.7 0.9260.04 8.261.4 4
aWT b-aV259A8 . 8 61.6 31613 3 681 . 0 60.3 2.260.3 11.061.1 3
aV259A b-aWT 12.062.5 37661 0 9 7 6314 33612 1.760.3 8.961.5 4
aWT aB-bV259A8 . 9 62.4 43631 8 621 . 1 60.3 2.260.3 9.864.9 3
aV259A aB-bWT 4.860.6 27621 8 6 621 11.662.7 1.160.0 5.560.9 5
aWT aT-bV259A8 . 5 61.8 36631 6 621 . 1 60.2 2.360.1 1463.0 4
aV259A aT-bWT 3.761.6 25644 5 5 611 33631 . 4 60.2 6.061.7 4
279
aWT bY279A6 . 3 60.3 42621 3 641 . 2 60.4 2.460.1 8.061.3 3
aY279A bWT NA NA 27806140 253657 1.160.0 2.061.0 4
aWT a-bY279A4 . 9 60.3 39653 3 691 . 7 60.6 1.360.3 6.963.1 4
aY279A a-bWT NA NA 6606219 35613 0.7860.03 5.761.3 4
aWT b-aY279A2 2 674 8 648 8 629 2.761.1 2.160.6 6.561.6 3
aY279A b-aWT NA NA 72866188 220651 1.060.1 1.360.3 4
RM/W =E C 50 of mutant GlyR with 249,2 5 9 or 279 Ala substitution divided by EC50 of its relevant WT forms without Ala substitution.
NA, Not applicable since no glycine-induced current could be detected in the homomeric aY279A GlyR.
doi:10.1371/journal.pone.0028105.t001
b Subunit in a1 b Glycine Receptor Channel Gating
PLoS ONE | www.plosone.org 4 November 2011 | Volume 6 | Issue 11 | e28105this, we examined conformational changes that the M2–M3 loops
of the a1 and b subunits experienced during channel gating by
using voltage-clamp fluorometry (VCF). VCF correlates confor-
mational changes occurring at the gate with those occurring in
some other domain of interest in real-time [31,32]. A rhodamine
fluorescent dye was used to label the M2–M3 loop, because
rhodamine fluorescence exhibits an increase in quantum efficiency
as the hydrophobicity of its environment is increased. Thus,
rhodamine fluorescence intensity reports local conformational
changes that cause a change in its immediate chemical
microenvironment. These experiments were carried out in Xenopus
oocytes as fluorescence detection is not routinely possible in
HEK293 cell-expressed GlyRs [32].
Previously we reported that rhodamine methanethiosulfonate
(MTSR), when attached to the cysteine-substituted 199 residue in
the homomeric a1 GlyR via a disulfide bond, exhibited an
increase in fluorescence intensity upon glycine binding [33]. As the
current and fluorescence glycine concentration-response relation-
ships overlapped, we concluded that the fluorophore reported
M2–M3 loop conformational changes associated with channel
gating.
Cysteine mutations were introduced into either the a1o rb
subunits at the 199 position, and the mutant subunits were co-
expressed with the respective WT b or a1 subunits. As shown in
Fig. 3A and B, for the a1R199C b GlyR, where the fluorophore
reports conformational changes of the a1 M2–M3 loop, the
fluorescence intensity was increased upon glycine application.
Moreover, the concentration-response curves of fluorescence and
current overlapped and the respective glycine EC50 value was not
significantly different from each other (329657 mM and
396631 mM, respectively, p.0.05, Table 2). This implies that
the conformational changes of the a1 M2–M3 loop are coupled to
the channel gating in the a1 b GlyR, which is similar to the
situation previously demonstrated in the homomeric a1R199C
GlyR [33]. In contrast, in the a1 bA199C GlyR, where the
fluorophore reports conformational changes of the b M2–M3
loop, although the fluorescence intensity was increased upon
glycine application as in the a1R199C b GlyR, the concentration-
response curve of the fluorescence was dramatically right-shifted
relative to that of the current (Fig. 3C and D). The fluorescence
glycine EC50 value was 8.861.9 times larger than that of current
(40.768.3 versus 4.6160.26 mM, p,0.01, Table 2). These data
imply that conformational changes of the b M2–M3 loop are
uncoupled from channel gating in the a1 b GlyR. The degree of
uncoupling is reflected by the ratio of glycine EC50 values between
fluorescence and current (RF/I). These values were 1.260.2 and
8.861.9 (Fig. 3E and Table 2) for the a1 and b subunits,
respectively, which suggests that the gating signal takes the a1
subunit’s gating pathway to activate the channel, whereas it
bypasses the b subunit’s gating pathway.
Structural basis of the lower sensitivity of a1 b GlyR
channel function to hyperekplexia-mimicking mutations
introduced into the M2–M3 loop of the b than into the
a1 subunit
We investigated whether the minor role of the b subunit in a1 b
GlyR channel gating was due to structural differences in the ECD
or TMD. To address this question, we constructed two chimeras of
a1 and b subunits (Fig. 4A and Fig. S1). Chimera a–b comprises
the ECD of the a1 subunit and the TMD (including the M3–M4
domain) of the b subunit. Conversely, chimera b–a comprises the
ECD of the b subunit and the TMD of the a1 subunit. We then
investigated how these chimeras mimicked the b subunit to
contribute to a1 b GlyR channel gating, by co-expressing each
chimera with the a1 subunit (10:1 ratio) and examining the RM/Ws
of the hyperekplexia-mimicking mutations introduced into the a1
and chimeric subunits. It is worth noting that neither chimera,
when transfected alone into HEK293 cells, induced any current
upon the application of glycine at concentrations up to 100 mM
(data not shown).
When the K249A mutation was introduced, the glycine EC50so f
the a1K249A a-bWT and a1WT a-bK249A GlyRs were 83619
and 2564 mM, respectively. The relevant RM/Ws of the a1 and a-
b subunits in the a1 a-b GlyR were 4.361.3 and 1.360.3 (Fig. 4B
and Table 1), respectively. On the other hand, the glycine EC50s
of the a1K249A b-aWT and a1WT b-aK249A GlyRs were
6846157 and 36610 mM, respectively. The relevant RM/Wso f
the a1 and b-a subunits in the a1 b-a GlyR were 2167 and
1.160.4 (Fig. 4B and Table 1), respectively. These data contrast
dramatically with the corresponding values (45612 and 1.260.3)
calculated for the a1 b GlyR (Fig. 4B and Table 1). The RM/Wso f
the a1 subunit in both the a1 a-b and a1 b-a GlyRs were
significantly less than that of the a1 b GlyR (Fig. 4B, p,0.01 and
p,0.05, respectively), suggesting that when the gating pathway is
disrupted in the a1 subunit, both the a-b and b-a subunits
partially restore channel gating efficacy to that of the WT a1
GlyR. Both the a-b and b-a subunits therefore behave less like the
b subunit but more like the a1 subunit. This trend was also found
when the other two mutations, V259A and Y279A, were
investigated in the same way (Fig. 4C, D and Table 1).
It is worth noting that the a-b subunit behaves more like the a1
subunit than does the b-a subunit, based on their abilities to
compensate the disrupted gating pathway in the accompanying a1
subunit (Fig. 4B–D). Indeed, the difference in the a1 subunit
RM/Ws between the a1 b-a and a1 b GlyRs was so minor that it
was not even significant in the case of the Y279A mutation
(Fig. 4D). Taken together, it seems that the ECD plays a more
important role than the TMD in determining the minor role of the
b subunit in a1 b GlyR channel gating.
We further dissected the ECD to determine which subdomains
contributed to the b subunit’s minor role in a1 b GlyR channel
gating. The ECDs of the Cys-loop receptors comprise agonist
binding sites at subunit interfaces and transition zones, which relay
the agonist-binding information to the channel pore. The agonist
binding site is formed by the loops A, B, and C from the (+)
subunit interface and loops D, E and F from the (-) subunit
interface, while the transition zone is formed by loop 2, the
conserved Cys-loop and the pre-M1 linker [7,10,11,12,13,15,16].
The agonist binding site and transition zone have been shown to
function as relatively independent modules [11]. We therefore
investigated which domain might be responsible for the minor role
of the b subunit in a1 b GlyR channel gating. To achieve this, two
chimeras were constructed. Chimera aB-b comprised the a1
subunit agonist binding site and the b subunit transition zone and
TMDs, while chimera aT-b comprised the a1 subunit transition
zone and the b subunit agonist binding site and TMDs (Fig. 4A
and Fig. S1). Both chimeras were co-expressed with the a1V259A
subunit, and the ability of each to compensate the disrupted
channel gating pathway of the accompanying a1 subunits was
examined. The V259A mutation was investigated here because,
among the K249A, V259A and Y279A mutations, the a1V259A
subunit showed the largest difference in RM/W between the
a1V259A b and a1V259A a-b GlyRs (Fig. 4B–D and Table 1). We
therefore expected this mutation would most clearly distinguish
the aB-b or aT-b subunits from the b or a-b subunits when
comparing their abilities to compensate the disrupted gating
pathway in the accompanying a1 subunits.
b Subunit in a1 b Glycine Receptor Channel Gating
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the a1V259A aB-bWT and a1V259A aT-bWT GlyRs were
186621 and 455611 mM, respectively. The relevant RM/Wso f
the a1V259A subunit were 11.662.7 and 3363, respectively, both
of which are significantly less than that of the a1V259A b GlyR
(71620, p,0.01 and p,0.05, respectively). This indicates that
both chimeras compensate the disrupted channel gating pathway
in the a1V259A subunit to some degree, but neither of them to the
same extent as the a-b subunit (Fig. 4C and Table 1). It is thus
evident that both the agonist binding domain and the transition
zone of the ECD contribute to the b subunit’s minor role in a1 b
GlyR channel gating.
The structural basis of the uncoupling of b subunit
M2–M3 loop conformational changes from a1 b GlyR
channel gating
As noted above, the reduced sensitivity of a1 b GlyR channel
function to hyperekplexia-mimicking mutations introduced into
the b subunit was mirrored by the uncoupling of the b M2–M3
Figure 3. VCF of a1 b GlyRs. Example current and fluorescence traces of the a199C b and ab 199C GlyRs are shown in (A) and (C), respectively.
Averaged normalized glycine concentration-response curves of current and fluorescence of the a199Cb and ab 199C GlyRs are shown in (B) and (D),
respectively. The RF/Is (the EC50 of fluorescence divided by the EC50 of current) of the a199C b and ab 199C GlyRs are plotted (E). (** p,0.01 using the
Student’s t-test).
doi:10.1371/journal.pone.0028105.g003
b Subunit in a1 b Glycine Receptor Channel Gating
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VCF examination. We next investigated the structural basis for
this uncoupling using the same chimera strategy as described in
the previous section. We used VCF to monitor conformational
changes experienced by the labeled 199C residues of the a-b, b-a,
aB-b and aT-b subunits when they were co-expressed with the a1
Table 2. Properties of glycine induced currents and fluorescences of MTSR-labeled GlyRs recorded in oocytes.
Constructs Current Fluorescence RF/I n
EC50 (mM) nH Imax (mA) EC50 (mM) nH Fmax (%)
a199C bWT 329657 1.2060.16 3.5160.24 396631 0.9760.04 9.4260.53 1.260.2 8
aWT b199C 4.6160.26 2.7360.38 2.4660.19 40.768.3 1.4760.12 7.5860.84 8.861.9 10
aWT a-b199C 4.4660.43 2.3660.32 1.5360.09 6.1561.08 2.1060.13 6.5861.17 1.460.3 8
aWT b-a199C 22.261.7 2.2660.11 3.1960.08 92.165.5 1.1560.05 3.8660.37 4.160.4 9
aWT aB-b199C 3.8260.32 2.1160.11 2.5760.14 18.061.9 1.1960.12 8.5261.07 4.760.6 7
aWT aT-b199C 2.0760.23 1.4560.06 2.1960.20 14.061.0 2.3160.06 11.560.6 6.860.9 8
RF/I =t h eE C 50 of fluorescence divided by the EC50 of current.
doi:10.1371/journal.pone.0028105.t002
Figure 4. Effects of M2–M3 loop mutations on chimeric a1 b GlyR channel function. (A) The molecular identity of each chimera is
schematically illustrated, with green and red denoting a1 and b subunit sequences, respectively. (B–D) The RM/Ws (the EC50 of the mutant chimeric a1
b GlyR divided by the EC50 of its relevant WT chimeric a1 b GlyR) resulting from introducing the K249A, V259A or Y279A mutation. The symbol (#)
represents constructs containing WT a1 and mutant b or other indicated chimeric subunit, while the symbol (N) represents constructs containing
mutant a1 and WT b or other indicated chimeric subunit. (* p,0.05; ** p,0.01; n.s.d. not significantly different; using the Student’s t-test).
doi:10.1371/journal.pone.0028105.g004
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fluorescence changes could be detected from any of these chimeric
subunits when expressed alone in oocytes (data not shown).
Therefore, the fluorescence and current changes we detected when
they were co-expressed with the a1 subunit must have arisen from
heteromers formed with the a1 subunit.
As shown in Fig. 5A and C, in the a1 a-b199C GlyR, the
fluorescence and current EC50 values were 6.1561.08 and
4.4660.43 mM, respectively, and the RF/I was 1.460.3 (Table 2).
On the other hand, in the a1 b-a199C GlyR, the fluorescence and
current EC50 values were 92.165.5 and 22.261.7 mM, respec-
tively, and the RF/I was 4.160.4 (Fig. 5B and C and Table 2). The
RF/Is of both the a-b and b-a subunits were significantly less than
that of the b subunit, whose RF/I was 8.861.9 (p,0.01 and
p,0.05, respectively). This implies that both the ECD and TMD
contribute to the uncoupling of the b subunit’s M2–M3
conformational changes from the channel gating. The ECD,
however, might play a major role since the RF/I of the a-b subunit
is not significantly different from that of the a subunit (p.0.05),
while the b-a subunit RF/I is closer to that of the b subunit
(Fig. 5C). This is consistent with the suggestion that the ECD
dominates in determining the minor role of the b subunit in a1 b
GlyR channel gating, obtained from the hyperekplexia-mimicking
mutation experiments described above.
When further dissecting the ECD, in the a1 aB-b199C GlyR,
the fluorescence and current EC50 values were 18.061.9 and
3.860.3 mM, respectively, and the RF/I was 4.760.6 (Fig. 5C and
Table 2). On the other hand, in the a1 aT-b199C GlyR, the
fluorescence and current EC50s were 14.061.0 and 2.160.2 mM,
respectively, and the RF/I was 6.860.9 (Fig. 5C and Table 2). The
RF/Is of both chimeras lay between those of the a1 and b subunits
(1.260.2 and 8.861.9, respectively), which implies that both the
agonist binding site and transition zone contribute to the
uncoupling of the b subunit’s M2–M3 conformational changes
from the channel gating. It is noteworthy that the transition zone
might play a minor role, as the RF/I of the a1 aT-b199C GlyR was
not statistically significantly different from that of the a1 b199C
GlyR (p.0.05, Fig. 5C).
Discussion
b subunit plays a minor role in a1 b GlyR channel gating
To investigate how the a1 and b subunits each contribute to the
channel gating, we assumed that the more a certain subunit
contributes to channel gating, the more channel function is
compromised when the gating pathway is disrupted in this subunit.
By introducing hyperekplexia-mimicking mutations to the M2–
M3 loops of the a1 and b subunits, we found that disrupting the
channel gating pathway within the a1 subunit had drastic effect on
the overall a1 b GlyR function, whereas disrupting the channel
gating pathway via the corresponding mutations within the b
subunit had little effect. Thus, our results suggest that the a1
subunit dominates channel gating while the b subunit plays only a
minor role. Asymmetrical contributions to Cys-loop receptor
gating have previously been suggested in the nAChR. For
example, cryo-electron microscopic structure analysis shows that
the M2 pore-lining domains of the a subunits engage a rotation
relative to those of the non-a subunits during channel gating [16],
and single channel recording analysis shows a negligible coupling
between the pre-M1 linker, the Cys-loop and the M2–M3 loop in
the non-a subunits [14]. Our results imply that the a1 subunit of
the GlyR behaves like the a subunit of the nAChR, while the b
subunit of the GlyR behaves like the non-a subunits of the
nAChR.
Figure 5. VCF of chimeric a1 b GlyRs. Averaged, normalized glycine
concentration-response curves of current and fluorescence of aa -b199C
and ab -a199C GlyRs are shown in (A) and (B), respectively. (C) The RF/Is
(the EC50 of fluorescence divided by the EC50 of current) of the a199C b,
ab 199C, aa -b199C, ab -a199C, aa B-b199C and aa T-b199C GlyRs are
plotted. (* p,0.05; ** p,0.01; n.s.d. not significantly different, using
the Student’s t-test).
doi:10.1371/journal.pone.0028105.g005
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asymmetrical contribution of the a1 and b subunits to channel
gating. We found that the concentration of agonist required to
induce a change in fluorescence of the fluorophore attached to the
b subunit is higher than that required to activate the channel. In
contrast, the corresponding fluorescence and current concentra-
tion-response curves are overlapping when the a1 subunit is
labeled. Such an uncoupling of M2–M3 conformational changes
from the agonist-induced channel gating has also been demon-
strated in the b subunit of the nAChR [34]. A possible explanation
for such an uncoupling is that when two or three agonist binding
sites are occupied by a low concentration of agonist, the gating
pathway is activated along the a1 subunit and the channel is
activated. This channel activation might have reached its
maximum, since it has been shown that two or three bound
agonists are required for full activation of homomeric a1
[35,36,37,38] and heteromeric a1 b GlyRs [39]. In addition, a
recent study has shown that in the homomeric a7nAChR-5HT3A
receptor, three occupied agonist binding sites at nonconsecutive
subunit interfaces are required to exhibit maximal mean channel
open time [40]. Therefore, the binding of additional (4th and 5th)
agonists when a high concentration of agonist is present, which
leads to the gating pathway activation of the b subunit, would not
further the channel opening. In other words, a functional b
subunit is dispensable, and further disruption of this gating
pathway would have no effect on the overall channel gating of the
a1 b GlyR.
There is a possibility that fluorescence changes in the a1 b199C
GlyR reflect conformational changes when the channel is
desensitized, as both desensitization and fluorescence change
appeared only when a high-concentration of glycine was applied
(Fig. 3C). However, we consider this is unlikely since fluorescence
changes occurred instantly while receptors accumulate in
desensitized states with a much slower time course (Fig. 3C).
Structural basis of the minor role of the b subunit in a1 b
GlyR channel gating
By testing chimeras constructed from the a1 and b subunits, we
found that both the ECD and TMD were responsible for the b
subunit’s minor role in a1 b GlyR channel gating (Fig. 4 and 5),
although it seems that the ECD plays a dominant role. We
originally suspected that the 199 residue might be the cause since
this residue is an Ala in the b subunit (Fig. 2A) and, in the a1
subunit, the R199A mutation has been shown to drastically
compromise a1 GlyR channel function and mimic the phenotype
of hyperekplexia-causing mutations [20]. However, when we
introduced the A199R mutation into the b subunit, the
contribution of the b subunit to the a1 b GlyR channel gating
was not changed (Table 1). Indeed, the natural existence of the
199A residue in the b subunit might be explained by the fact that,
since the b subunit M2–M3 loop is not involved in channel gating
and hence not sensitive to mutations, whether a gating-favorable
199R or gating-disfavorable 199A exists in the b subunit makes no
difference to a1 b GlyR channel gating. Instead, the ECD, which
is upstream from the M2–M3 loop in the gating pathway, plays a
major role in limiting the contribution of the b subunit to channel
gating.
When further dissecting the role of the ECD, our chimera
studies indicate that motifs in both the agonist binding site and
transition zone determine the contribution of the b subunit to
overall receptor gating (Fig. 4 and 5). Thus, no single domain is
responsible for the minor role of the b subunit in a1 b GlyR
channel gating. One possible explanation is that residues
contributing to its minor role are distributed throughout the b
subunit, including the agonist binding site, the transition zone and
the transmembrane channel pore domains (Fig. 4 and 5). As a
result, no single domain from the a1 subunit is able to completely
rescue the gating contribution of the b subunit to the level of the
a1 subunit.
From anevolutionaryperspective,wesuggest thatthereasonwhy
residues that disrupt the b subunit gating are distributed evenly
throughout its coding region is that the gating pathway within the b
subunit was not optimized to a ‘‘normal level’’ as in the a1 subunit,
when the b subunit joined the a1 subunit to form the heteromeric
a1 b GlyR. It has been speculated that ancestral Cys-loop receptors
were homomers [41,42] and that the ancestral GlyR might exist in
the homomeric a form. Alternatively, even if the gating pathway of
the b subunit was equivalent to that of the a1 subunit when the
heteromeric a1 b GlyR came into being, random mutations that
compromise its channel gating pathway could have accumulated
throughouttheb subunitduringevolution. Thisis because a normal
gating pathway within the b subunit is dispensable for a1 b GlyR
channel function and it would not serve as a constraint on the b
subunit during evolution. Thus, no single domain from the a1
subunit could rescue b subunit gating efficacy.
The GlyR b subunit is reminiscent of the non-a muscle nAChR
subunits, which have much higher ratios of the number of
nonsynonymous substitutions to that of synonymous substitutions
than the a muscle nAChR subunit, implying less functional
constraint on the non-a than a nAChR subunits during evolution
[43]. Another example is the AChBP, whose acetylcholine binding
but not gating pathway is the function subjected to evolutionary
pressure. When the AChBP is connected to the 5HT3R TMD, a
functional channel can be formed only if the disabled gating
pathway components in the AChBP are replaced by the
corresponding ones from the 5HT3R [11].
Implications for the distribution of hereditary
hyperekplexia-causing mutations in the a1 b GlyR
GlyR hereditary hyperekplexia-causing mutations have been
mapped almost exclusively onto the gene of the a1 to the exclusion
of the b subunit (Fig. 1). This is possibly because the gene of the a1
subunit is a hot spot, more amenable to genetic mutations than
that of the b subunit, but it seems more likely because mutations
occurring in the a1 subunit more drastically affect a1 b GlyR
channel function than those occurring in the b subunit. This
assumption is supported by our experiments showing that
hyperekplexia-mimicking mutations introduced into the b subunit
have much less effect on a1 b GlyR channel function than those
introduced into the a1 subunit.
More interestingly, most mutations identified on the a1 subunit
that affect channel function (rather than surface expression),
cluster either in domains associated with the channel gating
pathway (i.e., the M2–M3 loop, loop 2 and the pre-M1 linker) or
along the pore-lining M2 domain, but rarely occur in the agonist
binding sites (Fig. 1) [1,3,4]. This can be explained by the fact that
the a1 b GlyR has five potential agonist binding sites and only two
or three functional sites are required for efficient gating [17,39].
Thus, introducing mutations into the agonist binding sites of either
the a1o rb subunit will have no effect on overall a1 b GlyR
function [17]. In other words, the a1 and b subunits can
compensate each other at the agonist binding level, but this
compensation between the a1 and b subunits does not pass on to
the downstream channel gating pathway. In summary, our
experiments provide a possible explanation of why hereditary
hyperekplexia-causing mutations concentrate in the channel
gating pathway of the a1, to the exclusion of the b subunit, in
the a1 b GlyR.
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Mutagenesis and chimera construction of the GlyR
cDNAs
The human GlyR a1 and b subunit cDNAs were subcloned into
the pcDNA3.1zeo+ (Invitrogen) or pGEMHE [44] plasmid vectors
for expression in HEK293 cells or Xenopus oocytes, respectively.
Site-directed mutagenesis and chimera construction were per-
formed using the QuickChange (Stratagene, La Jolla, CA, USA)
mutagenesis and multiple-template-based sequential PCR proto-
cols, respectively.
The multiple-template-based sequential PCR protocol for
chimera construction was developed in our laboratory and has
recently been described in detail elsewhere [45]. This procedure
does not require the existence of restriction sites, or the
purification of intermediate PCR products, and needs only two
or three simple PCRs followed by general subcloning steps. Most
importantly, the chimera joining sites are seamless and the success
rate for construction is nearly 100%. The joining sites used in our
experiment were chosen based on the following principles: (1) A
site, based on the crystal structure of the AChBP [7], is to be near
the boundary between the two flanking loops to minimize
disturbance on the loop structures. (2) The pair of residues of a
joining site is to be conserved between the GlyR a and b subunits,
wherever possible. The joining sites used in our experiment are
between the following pairs of residues: a L135–T136 and b I157–
T158 for the N-terminus of the Cys-loop, a Q155–L156 and b
Q178–L179 for the C-terminus of the Cys-loop, a T208-C209 and
b T232-C233 for the N-terminus of the pre-M1 linker, and a
R218-Q219 and b R242-Q243 for the C-terminus of the pre-M1
linker (Fig. S1). The a R218-Q219 and b R242-Q243 are also the
joining sites for chimeras constructed between the ECD and
TMD. The loop 2 transposition was achieved by incorporating
either the aA52Q or bQ73A mutations, as the loop 2 sequences
between the a1 and b subunits are otherwise conserved.
For the VCF experiments, both GlyR a1 and b subunit cDNAs
in the pGEMHE vector were mutated to substitute non-essential
background cysteines with alanines, including a1C41A and
bC115AC291A [46,47].
For the b-a chimeras used for determining the effect of
hyperekplexia-mimicking mutations on a1 b GlyR channel
function, the Thr at the M2 69 position was replaced by a Cys.
Thr to Cys mutation at this site in the homomeric a1 GlyR does
not affect glycine activation, but does confer picrotoxin resistance
on the channel [30]. Through such a modification, picrotoxin
resistance was used to distinguish the heteromeric a1 b-a GlyR
from the homomeric a1 GlyR when the a1 and b-a subunits were
co-expressed.
HEK293 cell culture, expression and electrophysiological
recording
The effects of the hyperekplexia-mimicking mutations, K249A,
V259A and Y279A, were examined on GlyRs expressed in
HEK293 cells (ATCC). Details of the HEK293 cell culture, GlyR
expression and electrophysiological recording of the HEK293 cells
are described elsewhere [30]. Briefly, HEK293 cells were
maintained in DMEM supplemented with 10% fetal bovine
serum. Cells were transfected using a calcium phosphate
precipitation protocol. When co-transfecting the a1 together with
the b or any other chimera subunits, their respective cDNAs were
combined in a ratio of 1:10. In addition, the pEGFP-N1
(Clontech) was co-transfected to facilitate identifying the trans-
fected cells. Glycine-induced currents were measured using the
whole cell patch-clamp configuration. Cells were treated with
external Ringer’s solution and internal CsCl solution [30]. Cells
were voltage-clamped at 240 mV. When the heteromeric GlyRs
were expressed, the picrotoxin sensitivity was tested to confirm
that the majority of receptors are heteromers [29,30]. A 10 mMo r
100 mM concentration of picrotoxin was applied to the hetero-
meric GlyRs in the presence of glycine at the EC50 concentration
of their corresponding a1 homomers. Only the cells with
significant picrotoxin resistance compared with their a1 homo-
mers, e.g. where 100 mM picrotoxin inhibited the current by less
than 50%, were used for further glycine-sensitivity examination.
Oocyte preparation, expression and VCF recording
VCF experiments were performed on GlyRs expressed in
Xenopus laevis oocytes. Female Xenopus laevis frogs were purchased
from Xenopus Express, France. Details of oocyte preparation,
GlyR expression and VCF recording are described elsewhere [33].
Briefly, the mMessage mMachine kit (Ambion, Austin, TX) was
used to generate capped mRNA. The mRNA was injected into
oocytes of the female Xenopus laevis frog with 10 ng (1 ng a1 and
9n gb or any other chimeric subunits) per oocyte. After injection,
the oocytes were incubated in ND96 solution [33] for 3–4 days at
18 uC before recording.
The sulfhydryl-reactive reagent, sulforhodamine methanethio-
sulfonate (MTSR, Toronto Research Chemicals, North York,
Ontario, Canada), was used to label 199C residues. On the day of
recording, the oocytes were labeled with 10 mM MTSR for 25 s,
either in the absence or presence of glycine. The oocytes were then
transferred to the recording chamber and perfused with ND96
solution. The current was recorded by the two-electrode voltage
clamp configuration and the recording electrode was filled with
3 M KCl. Cells were voltage-clamped at 240 mV. The
fluorescence was recorded using the PhotoMax 200 photodiode
detection system (Dagan Corp., Minneapolis, MN).
Data analysis
Results are expressed as mean6standard error of the mean of
three or more independent experiments. The empirical Hill
equation, fitted by a non-linear least squares algorithm (SigmaPlot
9.0, Systat Software, Point Richmond, CA), was used to calculate
the EC50 and Hill coefficient (nH) values for glycine-induced
current and fluorescence change. Statistical significance was
determined using the Student’s t-test.
Supporting Information
Figure S1 Amino acid sequence alignment between the
human GlyR a1 and b subunits. The joining sites for chimera
construction are highlighted in blue. The K249, V259 and Y279
residues, where hyperekplexia-mimicking mutations were intro-
duced, are highlighted in red. The a1R199 and bA199 residues,
where the Cys mutation was introduced for VCF experiment, are
highlighted in green.
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